Log In
Print
BCIQ
Print
Print this Print this
 

AFM11

  Manage Alerts
Collapse Summary General Information
Company Affimed Therapeutics AG
DescriptionTetravalent bispecific human antibody that retargets cytotoxic T cells to tumor cells
Molecular Target CD19 ; CD3
Mechanism of ActionBinds CD19; Binds CD3
Latest Stage of DevelopmentPreclinical
IndicationNon-Hodgkin's lymphoma (NHL)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today